Screening for point mutations in the LDL receptor gene in Bulgarian patients with severe hypercholesterolemia

被引:13
作者
Mihaylov, VA
Horvath, AD
Savov, AS
Kurshelova, EF
Paskaleva, ID
Goudev, AR
Stoilov, IR
Ganev, VS
机构
[1] Med Univ Sofia, Dept Chem & Biochem, Sofia 1431, Bulgaria
[2] Med Univ Sofia, Univ Hosp Obstet & Gynaecol, Sofia 1431, Bulgaria
[3] Med Univ Sofia, Dept Propaedeut Internal Dis, Sofia 1431, Bulgaria
[4] Natl Ctr Cardiovasc Dis, Sofia, Bulgaria
[5] Univ Connecticut, Ctr Hlth, Dept Surg, Farmington, CT USA
关键词
familial hypercholesterolemia; LDL receptor; point mutations;
D O I
10.1007/s10038-004-0127-6
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Familial hypercholesterolemia (FH) is a common, autosomal dominant disorder of lipid metabolism, caused by defects in the receptor-mediated uptake of LDL (low-density lipoproteins) due to mutations in the LDL receptor gene (LDLR). Mutations underlying FH in Bulgaria are largely unknown. The aim of the present study was to provide information about the spectrum of point mutations in LDLR in a sample of 45 Bulgarian patients with severe hypercholesterolemia. Exons 3, 4, 6, 8, 9, and 14, previously shown to be mutational hot spots in LDLR, were screened using PCR-single-strand conformation polymorphism (SSCP). Samples with abnormal SSCP patterns were sequenced. Three different, hitherto undescribed point mutations (367T>A, 377T>A, 917C>A) and two previously described mutations (858C>A and 1301C>T) in eight unrelated patients were identified; four of the detected point mutations being missense mutations and one, a nonsense mutation. One of the newly described point mutations (917C>A) is a base substitution at a nucleotide position, at which two other different base substitutions have already been reported. Thus, all three possible base substitutions at this nucleotide position have been detected, making it a hot spot for point mutations causing FH. This is the first such mutational hot spot described in exon 6 of LDLR.
引用
收藏
页码:173 / 176
页数:4
相关论文
共 29 条
[1]   Cystic fibrosis mutations and associated haplotypes in Bulgaria - A comparative population genetic study [J].
Angelicheva, D ;
Calafell, F ;
Savov, A ;
Jordanova, A ;
Kufardjieva, A ;
Galeva, I ;
Nedkova, V ;
Ivanova, T ;
Yankova, P ;
Konstantinova, D ;
Genev, E ;
Kalaydjieva, L .
HUMAN GENETICS, 1997, 99 (04) :513-520
[2]  
[Anonymous], 1995, FAMILIAL HYPERCHOLES
[3]  
BRONZOVA J, 1994, HUM GENET, V93, P170
[4]   Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia [J].
Couture, P ;
Brun, LD ;
Szots, F ;
Lelièvre, M ;
Gaudet, D ;
Després, JP ;
Simard, J ;
Lupien, PJ ;
Gagné, C .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (06) :1007-1012
[5]  
Day INM, 1997, HUM MUTAT, V10, P116
[6]   The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia [J].
Heath, KE ;
Gudnason, V ;
Humphries, SE ;
Seed, M .
ATHEROSCLEROSIS, 1999, 143 (01) :41-54
[7]  
Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602
[8]   High frequency of the ApoB-100 R3500Q mutation in Bulgarian hypercholesterolaemic subjects [J].
Horvath, A ;
Savov, A ;
Kirov, S ;
Karshelova, E ;
Paskaleva, I ;
Goudev, A ;
Ganev, V .
JOURNAL OF MEDICAL GENETICS, 2001, 38 (08) :536-540
[9]   INFLUENCE OF SPECIFIC MUTATIONS AT THE LDL-RECEPTOR GENE LOCUS ON THE RESPONSE TO SIMVASTATIN THERAPY IN AFRIKANER PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA [J].
JEENAH, M ;
SEPTEMBER, W ;
VANROGGEN, FG ;
DEVILLIERS, W ;
SEFTEL, H ;
MARAIS, D .
ATHEROSCLEROSIS, 1993, 98 (01) :51-58
[10]   Spectrum of LDL receptor gene mutations in Denmark:: implications for molecular diagnostic strategy in heterozygous familial hypercholesterolemia [J].
Jensen, HK ;
Jensen, LG ;
Meinertz, H ;
Hansen, PS ;
Gregersen, N ;
Færgeman, O .
ATHEROSCLEROSIS, 1999, 146 (02) :337-344